Fresenius Kabi will supply its adalimumab biosimilar Idacio to Brazil’s public healthcare system through a new productive development partnership with Fiocruz/Bio-Manguinhos, a public health research institution, and Bionovis, a Brazilian biopharmaceutical company.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?